Dawson James Keeps Their Buy Rating on Cytosorbents (CTSO)
August 21 2022 - 08:26AM
TipRanks
In a report released on August 17, Jason Kolbert from Dawson James
maintained a Buy rating on Cytosorbents (CTSO - Research Report),
with a price target of $16.00. The company's shares closed last
Friday at $2.00.Kolbert covers the Healthcare sector, focusing on
stocks such as Mesoblast, Sorrento Therapeutics, and Can-Fite
BioPharma. According to TipRanks, Kolbert has an average return of
-1.6% and a 36.32% success rate on recommended stocks. Cytosorbents
has an analyst consensus of Moderate Buy, with a price target
consensus of $12.50, a 525.00% upside from current levels. In a
report released on August 3, H.C. Wainwright also maintained a Buy
rating on the stock with a $9.
https://www.tipranks.com/news/blurbs/dawson-james-keeps-their-buy-rating-on-cytosorbents-ctso?utm_source=advfn.com&utm_medium=referral
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Jan 2023 to Feb 2023
CytoSorbents (NASDAQ:CTSO)
Historical Stock Chart
From Feb 2022 to Feb 2023